HIGHLIGHTS
- who: Tongyi Zhang from the Oncology, Italy University of Florence, Italy have published the research work: RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report, in the Journal: (JOURNAL) of 20/05/2021
- what: This is the first case report in which a patient with only the TRIM33-RET fusion, a single fusion gene, detected in PDAC had a remarkable response to pralsetinib.
SUMMARY
Pancreatic cancer has a high degree of malignancy and rapid progression. The progression-free survival (PFS) for first-line chemotherapy in advanced pancreatic . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.